Literature DB >> 31862812

Sertraline-induced hypersensitivity pneumonitis.

Gursharan Virdee1, John Bleasdale2, Mohammed Ikramullah3, Emma Graham-Clarke2.   

Abstract

Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis, is a granulomatous, non-IgE-mediated hypersensitivity reaction of the alveoli and distal bronchioles presenting as an acute, subacute or chronic condition. It is most commonly associated with exposure to extrinsic allergens (eg, avian dust, mould and tobacco) and medications including antiarrhythmics (eg, amiodarone), cytotoxics (eg, methotrexate) and antiepileptics (eg, carbamazepine). Individuals diagnosed with this condition can present with severe hypoxia and respiratory failure. The fundamental principle of management is to remove the causative allergen. Evidence implicating selective serotonin reuptake inhibitors as a causative agent is limited, and this case report describes a rare clinical presentation of HP associated with sertraline, how it was diagnosed and subsequently treated. It is anticipated that raising awareness of this interaction will assist multidisciplinary teams, managing patients diagnosed with HP, to be more cognisant of sertraline as being an aetiological factor for this condition. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Unwanted effects / adverse reactions; adult intensive care; interstitial lung disease; psychiatry (drugs and medicines); respiratory medicine

Mesh:

Substances:

Year:  2019        PMID: 31862812      PMCID: PMC6936525          DOI: 10.1136/bcr-2019-230724

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Hypersensitivity pneumonitis: Antigen diversity and disease implications.

Authors:  R Nogueira; N Melo; H Novais E Bastos; N Martins; L Delgado; A Morais; P C Mota
Journal:  Pulmonology       Date:  2018-08-17

2.  Morphological and functional determinants of fluoxetine (Prozac)-induced pulmonary disease in an experimental model.

Authors:  Marco A Capelozzi; Edna A Leick-Maldonado; Edwin R Parra; Mílton A Martins; Iolanda F L C Tibério; Vera L Capelozzi
Journal:  Respir Physiol Neurobiol       Date:  2006-10-23       Impact factor: 1.931

3.  Venlafaxine-associated interstitial pneumonitis.

Authors:  Rachel C Turner; Jeffery E Nelson; Bruce T Roberts; David M Gillam
Journal:  Pharmacotherapy       Date:  2005-04       Impact factor: 4.705

Review 4.  Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.

Authors:  Moisés Selman; Annie Pardo; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

5.  Pulmonary fibrosis associated with psychotropic drug therapy: a case report.

Authors:  Clare Thornton; Toby M Maher; David Hansell; Andrew G Nicholson; Athol U Wells
Journal:  J Med Case Rep       Date:  2009-11-16

6.  The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study.

Authors:  Jette B Kornum; Steffen Christensen; Miriam Grijota; Lars Pedersen; Pia Wogelius; Annette Beiderbeck; Henrik Toft Sørensen
Journal:  BMC Pulm Med       Date:  2008-11-04       Impact factor: 3.317

7.  Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine.

Authors:  Pedro Gonçalo Ferreira; Susana Costa; Nuno Dias; António Jorge Ferreira; Fátima Franco
Journal:  J Bras Pneumol       Date:  2014 May-Jun       Impact factor: 2.624

Review 8.  Hypersensitivity pneumonitis: a complex lung disease.

Authors:  Gian Galeazzo Riario Sforza; Androula Marinou
Journal:  Clin Mol Allergy       Date:  2017-03-07

9.  Spotlight on the diagnosis of extrinsic allergic alveolitis (hypersensitivity pneumonitis).

Authors:  Xaver Baur; Axel Fischer; Lygia T Budnik
Journal:  J Occup Med Toxicol       Date:  2015-04-20       Impact factor: 2.646

10.  The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case-control study.

Authors:  Ted Rosenberg; Rory Lattimer; Patrick Montgomery; Christian Wiens; Liran Levy
Journal:  Clin Interv Aging       Date:  2017-11-21       Impact factor: 4.458

  10 in total
  1 in total

Review 1.  Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.

Authors:  Huanhuan Yan; Rui Su; Hongwei Xue; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.